Docetaxel has been used to treat various malignancies, including melanoma, breast cancer, squamous cell cancer of the head and neck, soft tissue sarcoma, pancreatic ductal adenocarcinoma, and colon adenocarcinoma.1,2 Docetaxel promotes microtubule assembly and stabilization preventing depolymerization and results in accumulation of microtubules, interference with cell division, and cell death. Dose-limiting toxic effects include neutropenia and oral mucositis.2 Minor toxic effects of docetaxel use are infusion-related hypersensitivity reactions and cutaneous reactions. Cutaneous adverse effects include a maculopapular rash, erythema and edema followed by desquamation, dry skin, erythematous plaques, acral erythema, alopecia, onycholysis, and nail discoloration.1-3 The incidence of nail changes is approximately 35%.4
Jacob CI, Frunza Patten S. Nail Bed Dyschromia Secondary to Docetaxel Therapy. Arch Dermatol. 1998;134(9):1167–1168. doi:
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: